Updated on 1 September 2026
Predicting Preterm Birth in Seconds
COO at EveryBaby
China (Hong Kong)
About
EveryBaby has developed a handheld medical device that assesses a woman's risk of spontaneous preterm birth starting from 14 weeks of pregnancy, delivering a result in seconds with no blood draw and no laboratory processing required. The device uses electrical impedance spectroscopy combined with machine learning to read the cervix directly at the point of care.
Our 449-woman clinical study in the UK is complete, and we currently hold conditional regulatory approval in Abu Dhabi. EveryBaby is headquartered in Hong Kong.
We are currently raising our seed round to advance further regulatory submissions, expand clinical validation into additional markets, and scale manufacturing ahead of commercial launch. We welcome conversations with investors focused on medtech, diagnostics, and women's health.
Project Location
- China (Hong Kong)
Project Website
https://www.every-baby.com/
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Medical Technology
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Convertible Loan
- Direct Equity Investment
Preferred Financing Model
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Bootstrapping
Main Service(s) Required
- Financial Services
Financial Services
- Private Equity & Venture Capital
Attached files
Organisation
China (Hong Kong)
Similar opportunities
Project
- Yes
- Yes
- Technology
- Private Project
- Islamic Finance
- Equity (private)
- Medical Technology
- Financial Services
- Open for negotiation
- Open for Negotiation
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- Feasibility Study Completed
- Private Equity & Venture Capital
Dabriel Choi
CEO at EveryBaby
China (Hong Kong)
Project
Project for Potential Osteoarthritis Global Player
- No
- Yes
- Equity
- Bio-Tech
- Technology
- Bootstrapping
- Private Project
- Financial Services
- Open for negotiation
- Open for Negotiation
- 50,000,001 USD or above
- Direct Equity Investment
- 25,000,001 to 50,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
Seungtaek NA
CEO at StarryBio
South Korea
Project
Focused Ultrasound for Next-Generation Radiotherapy
- No
- Yes
- Technology
- Private Project
- Equity (private)
- Financial Services
- Investment / Financing Discussion
Carmen Ng
CEO at CAPRiser Group
Canada